Novel Migraine Treatments: A Review

IF 2.4 3区医学 Q2 DENTISTRY, ORAL SURGERY & MEDICINE Journal of Oral & Facial Pain and Headache Pub Date : 2023-01-01 DOI:10.11607/ofph.3163

Naveen George, Stewart J Tepper

{"title":"Novel Migraine Treatments: A Review","authors":"Naveen George, Stewart J Tepper","doi":"10.11607/ofph.3163","DOIUrl":null,"url":null,"abstract":"Aims: To present a review of the mechanisms of action, available clinical data, and safety profiles of novel migraine therapeutics to inform practice. Methods: PubMed, Medline, and Google Scholar were searched for randomized controlled trials (24 publications), review articles (15 publications), and other pertinent literature (16 publications) discussing the novel migraine therapeutics available between the years 2010 and 2021. All publications were reviewed to assess the mechanism of action, relevant clinical data, and side effect profile for each novel treatment. Therapeutic gain was also recorded in studies that included a placebo arm. Results: A total of 55 studies were included in the final analysis. In the preventive treatment of migraine, novel medications target calcitonin gene-related peptide (CGRP) and fall into either the monoclonal anti-CGRP or gepant class. For the acute treatment of migraine, novel medications fall into either the ditan or gepant class. Several medical devices have been developed for the acute and preventive treatment of migraine. Conclusion: Novel therapeutics are available for both the prevention and acute treatment of migraine headaches. These new medications and neuromodulatory devices appear overall to be safe and effective in the management of migraine headaches.","PeriodicalId":48800,"journal":{"name":"Journal of Oral & Facial Pain and Headache","volume":"37 1","pages":"25-32"},"PeriodicalIF":2.4000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10586574/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Oral & Facial Pain and Headache","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.11607/ofph.3163","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Aims: To present a review of the mechanisms of action, available clinical data, and safety profiles of novel migraine therapeutics to inform practice. Methods: PubMed, Medline, and Google Scholar were searched for randomized controlled trials (24 publications), review articles (15 publications), and other pertinent literature (16 publications) discussing the novel migraine therapeutics available between the years 2010 and 2021. All publications were reviewed to assess the mechanism of action, relevant clinical data, and side effect profile for each novel treatment. Therapeutic gain was also recorded in studies that included a placebo arm. Results: A total of 55 studies were included in the final analysis. In the preventive treatment of migraine, novel medications target calcitonin gene-related peptide (CGRP) and fall into either the monoclonal anti-CGRP or gepant class. For the acute treatment of migraine, novel medications fall into either the ditan or gepant class. Several medical devices have been developed for the acute and preventive treatment of migraine. Conclusion: Novel therapeutics are available for both the prevention and acute treatment of migraine headaches. These new medications and neuromodulatory devices appear overall to be safe and effective in the management of migraine headaches.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

新的偏头痛治疗方法综述

目的:回顾偏头痛新疗法的作用机制、现有临床数据和安全性，为临床实践提供参考。方法:检索PubMed、Medline和谷歌Scholar，检索2010年至2021年间讨论新型偏头痛治疗方法的随机对照试验(24篇出版物)、综述文章(15篇出版物)和其他相关文献(16篇出版物)。对所有出版物进行审查，以评估每种新疗法的作用机制、相关临床数据和副作用概况。在包括安慰剂组的研究中也记录了治疗效果。结果:最终分析共纳入55项研究。在偏头痛的预防治疗中，新型药物以降钙素基因相关肽(CGRP)为靶点，分为抗CGRP单克隆类和抗CGRP类。对于偏头痛的急性治疗，新型药物分为地坦类和妊娠类。已经开发了几种用于偏头痛的急性和预防性治疗的医疗设备。结论:新的治疗方法可用于偏头痛的预防和急性治疗。总的来说，这些新的药物和神经调节装置在治疗偏头痛方面是安全有效的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Oral & Facial Pain and Headache DENTISTRY, ORAL SURGERY & MEDICINE-

CiteScore

5.10

自引率

4.00%

发文量

期刊介绍： Founded upon sound scientific principles, this journal continues to make important contributions that strongly influence the work of dental and medical professionals involved in treating oral and facial pain, including temporomandibular disorders, and headache. In addition to providing timely scientific research and clinical articles, the journal presents diagnostic techniques and treatment therapies for oral and facial pain, headache, mandibular dysfunction, and occlusion and covers pharmacology, physical therapy, surgery, and other pain-management methods.